Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of Oxabact in primary hyperoxaluria
NL-OMON31883Phase 3Not yet recruiting
- Sponsor
- OxThera AB
- Start
- Apr 2008
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of oxalobacter formigenes in Primary hyperoxaluria (PH), sponsored by OxThera AB. Primary endpoint: Safety with continued Oxabact exposure. Planned start Apr 2008; status: not yet recruiting.
02
Drugs
oxalobacter formigenes
03
Conditions
Primary hyperoxaluria (PH)
Beyond the preview
Go deeper on NL-OMON31883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31883.